Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
What it found
No result yet.
What was tested
Treatment tested
- Riboprine
Placebo
- Placebo
What it measured
Main measures
No evidence of disease activity (NEDA)
The time between month 3 and month 27 after initiation of supplementation.
Disability progressionRelapsesMRI lesions
Other measures (25)
Annualized relapse rate evaluated at month 27
The time between month 3 and month 27 after initiation of supplementation.
RelapsesTotal (cumulative) number of new or enlarged T2-weighted/FLAIR brain lesions per scheduled yearly MRI evaluated at month 27
The time between month 3 and month 27 after initiation of supplementation.
MRI lesionsSerum neurofilament light chain (sNfL)
Evaluated longitudinally at months 0, 3, 15 and 27.
Blood or spinal fluid markersPercentage of patients with disability improvement confirmed at 3 months
The time between month 3 and month 27 after initiation of supplementation.
Disability progressionThe time to onset of disability worsening confirmed at 3 months
The time between month 3 and month 27 after initiation of supplementation.
Disability progressionRelapsesCumulative change in EDSS score
The time between month 3 and month 24 after initiation of supplementation.
Disability progressionHow the body handles the medicineMultiple Sclerosis Functional Composite (MSFC)
The time between month 0 and month 24 after initiation of supplementation.
Disability progressionThinking and memoryWalking and mobilitySymbol Digit Modalities Test (SDMT)
The time between month 0 and month 24 after initiation of supplementation.
Thinking and memoryCalifornia Verbal Learning Test-II (CVLT-II)
The time between month 0 and month 24 after initiation of supplementation.
Thinking and memoryBrief Visuospatial Memory Test - Revised (BVMR-R)
The time between month 0 and month 24 after initiation of supplementation.
Thinking and memory
Who could take part
Relapsing MS · 18 to 65
Show the full criteria
Inclusion criteria
* Women and men ≥18 and ≤65 years of age * Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates) * Routinely treated and monitored for MS * Speak and read Danish * Deemed physically and mentally able to participate in this study
Exclusion criteria
* Active malignancy * Diagnosis of Crohn's disease and ulcerative colitis * Other comorbidities deemed to be relevant * Haematopoietic stem cell transplantation * Current or past treatment with non-MS related treatments deemed to be relevant * Pregnancy or lactation * People with MR contraindications: * Severe claustrophobia * Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
Papers
Loading reviews and guidelines…
History
- Result signal changed from Ongoing to Results published
Started
Jan 2026
Main results due
Jul 2028
Finished
Jul 2028